Protected classes, rebates and PBM reimbursement are just a few of the policies at risk, based on the Trump administration’s “Blueprint to Lower Prices and Reduce Out-of-Pocket Costs.” The scope of the blueprint surprised and concerned many, especially those in biopharmas and PBMs. If all the proposals are enacted, it could mean massive, controversial changes across the healthcare industry. Gain insights into the blueprint and its implications for various stakeholders–and the likelihood of its proposals actually becoming policy. HHS Secretary Azar has stated he has a “deep commitment” to pursue change. Find out what this means for pharma and PBMs moving into the next decade.